Last reviewed 2026-04-23 · How we verify

HF10 plus Ipilimumab

HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells.

HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells. Used for Unresectable or metastatic melanoma.

At a glance

Mechanism of action

The HSP90 inhibitor, HF10, targets and inhibits the heat shock protein 90, which is involved in the folding and stabilization of various proteins, including those involved in cancer cell growth and survival. The CTLA-4 inhibitor, Ipilimumab, blocks the activity of cytotoxic T-lymphocyte-associated protein 4, a protein that downregulates the immune response, thereby enhancing the immune response against cancer cells.

Approved indications

• Unresectable or metastatic melanoma

Common side effects

• Diarrhea
• Colitis
• Hypophysitis
• Adrenal insufficiency
• Nephritis

Key clinical trials

• A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma (PHASE2)
• A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.